CD274 and non-small cell lung carcinoma: Nowadays, the available data highlight at least five frontline immunotherapy options for NSCLC in real-world practice, thereby clinicians must carefully weigh out the tumor-specific attributes like PD-L1 expression, as well as treatment cost, and safety concerns, given the absence of superior biomarkers and survival data to guide their selection among these therapies.